FDA grants breakthrough therapy designation to pemvidutide in MASH

Altimmune, a biopharmaceutical company based in Gaithersburg, Maryland, announced on January 5, 2026, that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH ^[1]. The designation is meant to speed up development and review of drugs that show early evidence of major improvement over existing treatments for serious conditions ^[1].

Pemvidutide is not a semaglutide or tirzepatide medicine. It is a different type of injectable drug that activates both glucagon and GLP-1 receptors in a balanced 1:1 ratio, rather than acting on GLP-1 alone or with GIP ^[1]. According to Altimmune, the glucagon activity works directly on the liver to reduce fat, inflammation, and scarring, while the GLP-1 activity suppresses appetite and drives weight loss ^[1].

The FDA based its decision on 24-week data from the Phase 2b IMPACT trial, which found that pemvidutide produced a statistically significant resolution of MASH without worsening of liver fibrosis, along with early improvements in liver fat and non-invasive markers of fibrosis and inflammation ^[1]. In December 2025, Altimmune reported 48-week data showing continued improvement versus placebo in tests such as Enhanced Liver Fibrosis and Liver Stiffness Measurement, with further reductions seen from week 24 onward at both doses tested, which the company says supports ongoing antifibrotic activity ^[1]. At 48 weeks, patients on the 1.8 mg dose kept losing weight with no sign of a plateau, and the drug maintained a favorable side-effect profile, including a lower rate of people stopping treatment because of adverse effects compared with placebo ^[1].

Altimmune also said it completed an end-of-phase 2 meeting with the FDA last month and reached agreement on the design of a registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis ^[1]. The company plans to test multiple doses of pemvidutide over 52 weeks, using liver biopsy results as the trial's main measure, which could support a request for accelerated approval ^[1]. The Phase 3 trial is also expected to use AIM-MASH AI Assist, described as the first AI-based pathology tool the FDA has qualified for use in MASH studies ^[1].

Why it matters for patients

MASH is a progressive liver disease involving fat buildup, inflammation, and scarring that can advance to cirrhosis, liver failure, or liver cancer, and it is one of the leading reasons people in the U.S. need liver transplants ^[1]. Current treatment options do not fully address both the metabolic causes of the disease and the fibrosis that drives long-term risk, according to Altimmune ^[1].

For patients living with or at risk of MASH, this designation signals that regulators see potential in a drug that combines weight loss with direct liver benefits, distinct from GLP-1-only or GLP-1/GIP therapies already on the market. But it is important to note that pemvidutide remains investigational. It has not been approved for any use, and the current data come from a mid-stage trial with 48 weeks of follow-up, not the larger, longer studies still to come ^[1]. Breakthrough status can shorten the regulatory timeline, but it does not guarantee approval ^[1].

Altimmune is also studying pemvidutide separately for alcohol use disorder and alcohol-associated liver disease, with Phase 2 trials in those conditions already underway ^[1]. The company has not disclosed a price or a target approval date for any indication ^[1].

What happens next

Altimmune says it plans to start the Phase 3 registrational trial in MASH patients with moderate to advanced fibrosis, running for 52 weeks, and will separately seek scientific advice from European regulators before finalizing the trial protocol ^[1]. No specific start date or expected completion date for the Phase 3 study was given in the announcement ^[1].